ANI PHARMACEUTICALS INC (ANIP) Form 8-K — Aug 7, 2026

$ANIPForm 8-KItems 2.02, 7.01, 9.01Filed Aug 7, 2026, 7:00 AM ET0001023024-26-000068Original filing

ANI Pharmaceuticals reported record second-quarter 2026 results on August 7, 2026: net revenues of $266.0 million, up 25.9% year over year, with GAAP net income available to common shareholders of $24.7 million ($1.05 per diluted share) versus $8.1 million ($0.36) a year earlier. Adjusted non-GAAP diluted EPS rose to $2.21 from $1.80, and adjusted EBITDA climbed 32.4% to $71.6 million. Cortrophin Gel was the growth engine, with net revenues up 43.5% to $117.1 million, supported by a fully operational gout expansion that grew the Rare Disease sales force roughly 50% to about 180 reps targeting an estimated 285,000 addressable acute gout patients.

Key figures

Eps: $1.05 GAAP diluted; $2.21 adjusted non-GAAP diluted
Revenue: $266.0 million (Q2 2026 total net revenues)
Guidance: Reaffirmed FY2026: total net revenue $1,080-$1,140 million, adjusted non-GAAP EBITDA $285-$300 million, adjusted non-GAAP diluted EPS $9.19-$9.69; Cortrophin Gel net revenue guidance lowered to $520-$540 million (from $540-$575 million), implying 50-55% growth
Net Income: $24.7 million GAAP net income available to common shareholders (vs $8.1 million prior year)
Total Debt: $620.9 million principal value of outstanding debt, inclusive of senior convertible notes
Revenue Yoy: +25.9%
Total Assets: $1,494.1 million (June 30, 2026)
Cash Position: $360.2 million unrestricted cash and cash equivalents (June 30, 2026)
Shares Outstanding: 21.16 million basic weighted-average (Q2 2026); FY2026 adjusted EPS guidance assumes 21.5-21.8 million shares
Net leverage: ~1.0x as of 6/30/26
Brands revenue: $11.8 million, -10.5% YoY
Iluvien revenue: $18.7 million, -16.1% YoY on international shipment timing
Generics revenue: $99.1 million, +9.7% YoY
Gaap gross margin: 62.4%, down from 64.7% prior year
Cortrophin gel revenue: $117.1 million, +43.5% YoY
Ytd operating cash flow: $115.0 million
Adjusted non gaap ebitda: $71.6 million, +32.4% YoY
Gout addressable patients: ~285,000
Harmony agreement revenue: $17.7 million in Q2 ($8.0M development milestones + $9.7M pitolisant royalties); additional $2.0M expected in Q3 2026
Prior cortrophin guidance: $540-$575 million
Share repurchase authorization: $100.0 million through May 2029 (authorized May 8, 2026)
Rare disease salesforce expansion: Expanded ~50%, from ~120 reps to ~180 reps for gout

Price after filing

1 day: -2.0%7 days: -6.4%30 days: -10.8%

Close on the filing date to close N calendar days later (from $79.88). Historical, not a forecast.

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.